retatrutide obesity clinical trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide Achieves Up to 30.3%

[35] Etminan M, Takkouche B, Caamano-Isorna F

The limitations of our study include our small sample size, lack of information on antibiotic or probiotic use in the months preceding surgery in our population, inability to explore the function of the endometrial bacteria we recovered, and lack of healthy controls (inclusion of which may have helped determine if there is an endometrial microbiota in healthy women)

While the Virginia Tech researchers zeroed in on how GLP-1 drugs might alter alcohol absorption, companies in the behavior-change space may have a leg up on what (potentially) comes next

Wrigley S, Arafa D, Tropea D